5-alpha reductase inhibitors and prostate cancer mortality
Hamilton RJ, Chavarriaga J, Khurram N, Lau C, Luo J, Liu N, Komisarenko M, Kulkarni G, Wallis C, Juurlink DN, Fleshner N, Finelli A. JAMA Netw Open. 2024; 7(8):e2430223.
Publications
The impact of the early COVID-19 pandemic on healthcare system resource use and costs in two provinces in Canada: an interrupted time series analysis
Zeitouny S, Cheung DC, Bremner KE, Pataky RE, Pequeno P, Matelski J, Peacock S, Del Giudice ME, Lapointe-Shaw L, Tomlinson G, Mendlowitz AB, Mulder C, Tsui TCO, Perlis N, Walker JD, Sander B, Wong WWL, Krahn MD, Kulkarni GS. PLoS One. 2023; 18(9):e0290646. Epub 2023 Sep 8.
Initial healthcare costs for COVID-19 in British Columbia and Ontario, Canada: an interprovincial population-based cohort study
Tsui TCO, Zeitouny S, Bremner KE, Cheung DC, Mulder C, Croxford R, Del Giudice L, Lapointe-Shaw L, Mendlowitz A, Wong WWL, Perlis N, Sander B, Teckle P, Tomlinson G, Walker JD, Malikov K, McGrail KM, Peacock S, Kulkarni GS, Pataky RE, Krahn MD. CMAJ Open. 10(3):E818-30. Epub 2022 Sep 20.
Androgen deprivation therapy for prostate cancer: prescribing behaviors and preferences among urologists
Cheung DC, Martin LJ, Alibhai SMH, Komisarenko M, Dharma C, Niu Y, Warde P, Sridhar SS, Fleshner NE, Kulkarni GS, Finelli A. Can Urol Assoc J. 2022; May 20 [Epub ahead of print].
“Bring the hoses to where the fire is!”: differential impacts of marginalization and socioeconomic status on COVID-19 case counts and healthcare costs
Cheung DC, Bremner KE, Tsui TCO, Croxford R, Lapointe-Shaw L, Del Giudice L, Mendlowitz A, Perlis N, Pataky RE, Teckle P, Zeitouny S, Wong WWL, Sander B, Peacock S, Krahn MD, Kulkarni GS, Mulder C. Value Health. 2022; 25(8):1307-16. Epub 2022 May 5.
Opioid use after nephrectomy for kidney cancer in Ontario: a population-based study
Cheung DC, Martin LJ, Jivraj NK, Clarke H, Gomes T, Wijeysundera DN, Diong C, Nayan M, Saarela O, Alibhai SMH, Komisarenko M, Fleshner NE, Kulkarni GS, Finelli A. Urology. 2022; 164:118-23. Epub 2022 Feb 16.
Uptake of re-resection in T1 bladder cancer: an interrupted population-based time series analysis among different groups of surgeons
Wettstein MS, Baxter NN, Sutradhar R, Mamdani M, Song P, Qadri SR, Li K, Liu N, van der Kwast T, Hermanns T, Kulkarni GS. Urol Oncol. 2022; 40(4):165.e1-e8. Epub 2022 Feb 5.
The association of statin subgroups with lower urinary tract symptoms following a prostate biopsy
Goldberg H, Mohsin FK, Chandrasekar T, Wallis CJD, Klaassen Z, Ahmad AE, Saskin R, Kenk M, Saarela O, Kulkarni GS, Alibhai SMH, Fleshner N. Can Urol Assoc J. 2022; 16(5):E248-55. Epub 2021 Dec 21.
Oncological benefit of re-resection for T1 bladder cancer: a comparative effectiveness study
Wettstein MS, Baxter NN, Sutradhar R, Mamdani M. Song P, Qadri SR, Li K, Liu N, van der Kwast T, Hermanns T, Kulkarni GS. BJU Int. 2022; 129(2):258-68. Epub 2021 Oct 21.
Factors associated with re-resection in T1 bladder cancer: identifying patients who do not receive guideline-concordant care at the population level
Wettstein MS, Baxter NN, Sutradhar R, Mamdani M, Song P, Qadri SR, Bhalla G, Li K, Liu N, van der Kwast T, Hermanns T, Kulkarni GS. J Urol. 2022; 207(2):314-23. Epub 2021 Sep 22.